[Pidotimod in recurring respiratory infection in children with allergic rhinitis, asthma, or both conditions].
To demonstrate a decrease in the number of recurrent breathing infections in patients with allergic rhinitis and asthma, by means of the use of Pidotimod (a immunomodulator). Patients of both sexes, 2 to 16 years old, that had at least four episodes of acute respiratory infection, during the previous six months, administering a dose of 400 mg of pidotimod later, twice a day. It was identified a correlation between the number of cases of asthma and those of acute respiratory infection of r = 0.60 with a r2 = 40. A total of 73 patients of both sexes that presented allergic rhinitis and bronchial asthma, had developed at least four acute respiratory infection episodes. Form these patients, 33 were male, a rate that corresponded to 45%, and 40 were female, that corresponded to 55% of population. The average age was 6 years old, with a range from 2 to 16 years. The number of infectious events before using Pidotimod, was 422, with an average of 5.7 for patient, and later to its use, it was 295, that corresponded to 4.04 for each patient, in 6 months. The difference among the means was significant (p < 0.005). The number of days affected by each infectious event was of 446, with an average of 6.10 for patient, and later to administration of the product it was of 308 affected days, that corresponded to an average of 4.21 days for each patient, with a statistical significant of p < 0.001.